Skip to main content
HCPCS J9261 · Level II · Part B drug

HCPCS J9261: Injection, nelarabine, 50 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J9261

Billing unit
50 MG
Nelarabine injection
ASP payment limit
$40.872
October 2026; -37.5% vs July 2026
Practitioner MUE
80
MAI 3
OPPS status
SI K
APC 0825
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9261 is the Level II code for Injection, nelarabine, 50 mg, billed per 50 MG. The Medicare Part B ASP payment limit for October 2026 is $40.872 per billing unit, down 37.5% from July 2026. The practitioner MUE allows up to 80 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 0825. J9261 is billed in units of 50 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 20 NDCs to it, sold as Arranon, Nelarabine by Sandoz Inc., Sagent Pharmaceuticals, XGen Pharmaceuticals DJB, Inc.. No current Billing and Coding Article lists J9261, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9261 at $40.872 per 50 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $65.407 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9261
QuarterPayment limitPerCoinsurance
October 2026$40.87250 MG20%
July 2026$65.40750 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 20 NDCs from 10 labelers to J9261. Report the NDC in the claim's drug segment and bill the number of J9261 units that equals the quantity administered divided by 50 MG; the last column gives units per full package.

NDCs that crosswalk to J9261
NDCDrug nameLabelerPackage sizeBilling units / package
00078-0683-61ArranonSandoz Inc.50 × 15
25021-0259-50NelarabineSagent Pharmaceuticals50 × 15
25021-0259-51NelarabineSagent Pharmaceuticals50 × 630
39822-0650-01NelarabineXGen Pharmaceuticals DJB, Inc.50 × 15
39822-0650-06NelarabineXGen Pharmaceuticals DJB, Inc.50 × 630
43598-0142-06NelarabineDr. Reddy's Laboratories Inc.50 × 630
43598-0142-11NelarabineDr. Reddy's Laboratories Inc.50 × 15
62332-0813-50NelarabineAlembic Pharmaceuticals Inc.50 × 15
66758-0165-94ArranonSandoz Inc.50 × 15
70121-1743-04NelarabineAmneal Pharmaceuticals, LLC50 × 630
70710-1726-01NelarabineZydus Pharmaceuticals (USA) Inc.50 × 15
70710-1726-08NelarabineZydus Pharmaceuticals (USA) Inc.50 × 630
70710-1839-01NelarabineZydus Pharmaceuticals (USA) Inc.50 × 15
70710-1839-08NelarabineZydus Pharmaceuticals (USA) Inc.50 × 630
71288-0165-53NelarabineMeitheal Pharmaceuticals Inc.50 × 630
71288-0165-54NelarabineMeitheal Pharmaceuticals Inc.50 × 15
72205-0154-01NelarabineNovadoz Pharmaceuticals LLC50 × 15
72205-0154-04NelarabineNovadoz Pharmaceuticals LLC50 × 630
81927-0111-01NelarabineShorla Oncology Inc.50 × 15
81927-0111-06NelarabineShorla Oncology Inc.50 × 630

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9261. For practitioners the limit is 80 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9261 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services803 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital803 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9261 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J9261 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9261 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J9261 carries status indicator K and is assigned to APC 0825, with a published national unadjusted payment of $65.41. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J9261 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J9261 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Frequently asked questions — HCPCS J9261

What does HCPCS code J9261 describe?

J9261 is defined by CMS as "Injection, nelarabine, 50 mg". Each billing unit represents 50 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J9261 in October 2026?

The ASP-based payment limit is $40.872 per 50 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $65.407.

How many units of J9261 can be billed per day?

The practitioner Medically Unlikely Edit is 80 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9261?

The October 2026 ASP crosswalk lists 20 NDCs from 10 labelers: Arranon (Sandoz Inc.); Nelarabine (Sagent Pharmaceuticals); Nelarabine (XGen Pharmaceuticals DJB, Inc.); Nelarabine (Dr. Reddy's Laboratories Inc.). For example NDC 00078-0683-61 is a 50 package equal to 5 billing units. The crosswalk's billing-units-per-package figure converts each package into J9261 units.

Does J9261 have NCCI bundling edits?

No active practitioner PTP pairs list J9261 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.